Nordic Biotech

Nordic Biotech is a Copenhagen-based venture capital firm specializing in life sciences, biotechnology, and pharmaceutical investments. Founded in 2001, the firm has historically focused on late-stage clinical development programs and special situations within the Nordic region and the United States. The company is best known for its significant investment in Forward Pharma, which was involved in a high-profile patent dispute regarding dimethyl fumarate for multiple sclerosis. Nordic Biotech's portfolio has included diverse therapeutic areas such as neurology, metabolic disorders, and respiratory diseases through companies like Allon Therapeutics, Veloxis Pharmaceuticals, and Arriva Pharmaceuticals.